Your browser doesn't support javascript.
loading
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa, Bozena; Zietek, Marcin; Czarnecka, Anna M; Piejko, Karolina; Dziura, Robert; Galus, Lukasz; Ziólkowska, Barbara; Kieszko, Stanislaw; Kempa-Kaminska, Natasza; Calik, Jacek; Seredynska, Joanna; Gadek, Kamila; Zemelka, Tomasz; Teterycz, Pawel; Kubiatowski, Tomasz; Suwinski, Rafal; Mackiewicz, Jacek; Rutkowski, Piotr.
Afiliación
  • Cybulska-Stopa B; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Zietek M; Department of Oncology, Wroclaw Medical University, Wroclaw, Poland.
  • Czarnecka AM; Department of Surgical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Piejko K; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Dziura R; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
  • Galus L; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Ziólkowska B; Clinical Oncology Department, Holy Cross Cancer Center, Kielce, Poland.
  • Kieszko S; Department of Medical and Experimental Oncology, University of Medical Sciences, Poznan, Poland.
  • Kempa-Kaminska N; Chemotherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Calik J; II Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
  • Seredynska J; Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, Lublin, Poland.
  • Gadek K; Department of Clinical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Zemelka T; Department of Clinical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Teterycz P; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Kubiatowski T; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Suwinski R; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Mackiewicz J; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Rutkowski P; Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, Lublin, Poland.
J Dermatolog Treat ; 33(4): 2168-2174, 2022 Jun.
Article en En | MEDLINE | ID: mdl-34057374
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Reino Unido